其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Flavoxate CAS Registry Number: 15301-69-6 黄酮哌酯

CAS Name: 3-Methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid 2-(1-piperidinyl)ethyl ester
Additional Names: 3-methylflavone-8-carboxylic acid b-piperidinoethyl ester; 2-piperidinoethyl 3...
Literature References: Smooth muscle relaxant. Prepn of the hydrochloride: P. Da Re et al., J. Med. Pharm. Chem. 2, 263 (1960); P. Da Re, US 2921070 and US 3350411 (1960 to Recordati and 1967 to Seceph). Pharmacological studies: I. Setnikar et al., J. Pharmacol. Exp. Ther. 130, 356 (1960). Mechanism of action: P. Cazzulani et al., Arch. Int. Pharmacodyn. 274, 189 (1985). Pharmacokinetics in rats: I. Setnikar et al., Arzneim.-Forsch. 25, 1916 (1975); in man: M. Bertoli et al., Pharmacol. Res. Commun. 8, 417 (1976). In vivo activity: C. Pietra, P. Cazzulani, Farmaco Ed. Prat. 41, 267 (1986). Determn in tissues: A. Cova, I. Setnikar, Arzneim.-Forsch. 25, 1707 (1975). Clinical evaluations: D. V. Bradley, R. J. Cazort, J. Clin. Pharmacol. 10, 65 (1970); A. Zanollo, F. Catanzaro, Urol. Int. 35, 176 (1980). Clinical comparison with phenazopyridine: S. Gould, Urology 5, 612 (1975). Short review: R. Ruffmann, A. Sartini, Drugs Exp. Clin. Res. 13, 57 (1987).

Proxazole CAS Registry Number: 5696-09-3 普罗沙唑

CAS Name: N,N-Diethyl-3-(1-phenylpropyl)-1,2,4-oxadiazole-5-ethanamine
Additional Names: 5-[2-(diethylamino)ethyl]-3-(a-ethylbenzyl)-1,2,4-oxadiazole; propaxoline
Percent Composition: C 71.0...
Literature References: Smooth muscle relaxant. Prepn: GB 924608; Palazzo, Silvestrini, US 3141019 (1963, 1964 both to Angelini Francesco). Pharmacology: Silvestrini, Pozzatti, Arzneim.-Forsch. 13, 798 (1963). Separation and pharmacology of the enantiomers: De Feo et al., Farmaco Ed. Sci. 26, 370 (1971). Clinical trial in cerebrovascular insufficiency: G. Esposito, M. De Gregorio, Arzneim.-Forsch. 24, 1692 (1974).

Fenalamide CAS Registry Number: 4551-59-1 非那拉胺

CAS Name: a-[[[2-(Diethylamino)ethyl]amino]carbonyl]-a-ethylbenzeneacetic acid ethyl ester
Additional Names: N-[2-(diethylamino)ethyl]-2-ethyl-2-phenylmalonamic acid ethyl ester; ethyl N-[2-(di...
Literature References: Smooth muscle relaxant. Prepn: Galimberti et al., US 3025317 (1962 to Soc. Ital. Prod. Schering).

Thiphenamil CAS Registry Number: 82-99-5 S-(2-(二乙氨基)乙基)2,2-二苯基乙硫代酸酯

CAS Name: a-Phenylbenzeneethanethioic acid S-[2-(diethylamino)ethyl]ester
Additional Names: diphenylthioacetic acid S-(2-diethylaminoethyl) ester; diphenylthiolacetic acid 2-diethylaminoethyl e...
Literature References: Smooth muscle relaxant. Prepn: Richardson, US 2390555 (1945 to Wm. P. Poythress); Clinton, US 2510773 (1950 to Sterling Drug); Richardson, J. Pharm. Sci. 55, 1316 (1966). Mechanism of action study: Y. Kimoto et al., J. Urol. 144, 1497 (1990). Clinical evaluation in detrusor incontinence: C. E. Constantinou, Urol. Int. 48, 42 (1992).

Tiropramide CAS Registry Number: 55837-29-1 替瑞酰胺

CAS Name: a-(Benzoylamino)-4-[2-(diethylamino)ethoxy]-N,N-dipropylbenzenepropanamide
Additional Names: DL-a-benzamido-p-[2-(diethylamino)ethoxy]-N,N-dipropylhydrocinnamamide; O-(2-diethylaminoe...
Literature References: Smooth muscle relaxant; deriv of tyrosine. Prepn: F. Makovec et al., DE 2503992; eidem, US 4004008 (1975, 1977 both to Rotta). Activity on gastrointestinal motility: P. Senin et al., Gastrointestinal Motility in Health and Disease, H. L. Duthie, Ed. (University Park Press, Baltimore, 1978) pp 417-427. Mechanism of action: R. R. Vidal y Plana et al., J. Pharm. Pharmacol. 33, 19 (1981).

Moricizine CAS Registry Number: 31883-05-3 乙吗噻嗪

CAS Name: [10-[3-(4-Morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl]carbamic acid ethyl ester
Additional Names: 10-(3-morpholinopropionyl)phenothiazine-2-carbamic acid ethyl ester; ethmosine; e...
Literature References: Sodium channel blocker. Prepn: A. Gritsenko et al., DE 2014201 (1971 to Acad. Med. Sci., USSR), C.A. 76, 34273a (1972); eidem, US 3740395 (1973). Pharmacology and toxicity: N. V. Kaverina et al., Russ. Pharmacol. Toxicol. 35, 74 (1972). Mechanism of action study: T. Yamane et al., Br. J. Pharmacol. 108, 812 (1993). HPLC determn in plasma: C. C. Whitney et al., J. Pharm. Sci. 70, 462 (1981). Symposium on pharmacology, pharmacokinetics, clinical safety and efficacy: Am. J. Cardiol. 65, 1D-71D (1990). Review: C. A. Clyne et al., N. Engl. J. Med. 327, 255 (1992).

Bidisomide CAS Registry Number: 116078-65-0 比地索胺

CAS Name: a-[2-[Acetyl(1-methylethyl)amino]ethyl]-a-(2-chlorophenyl)-1-piperidinebutanamide
Additional Names: (±)-a-(o-chlorophenyl)-a-[2-(N-isopropylacetamido)ethyl]-1-piperidinebutyramid...
Literature References: Sodium channel blocker. Prepn: B. N. Desai et al., EP 170901; eidem, US 4639524 (1986, 1987 both to Searle); eidem, J. Med. Chem. 31, 2158 (1988). Cardiovascular pharmacology: L. G. Frederick et al., Cardiovasc. Res. 23, 897 (1989). Electrophysiologic study: S. M. Garthwaite et al., Drug Dev. Res. 27, 329 (1992). Bioavailability and tolerability in humans: R. L. Page et al., Clin. Pharmacol. Ther. 51, 371 (1992). Clinical pharmacokinetics: C. S. Cook et al., Pharm. Res. 10, 1675 (1993).

Propafenone CAS Registry Number: 54063-53-5 普罗帕酮

CAS Name: 1-[2-[2-Hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl-1-propanone
Additional Names: 2'-[2-hydroxy-3-(propylamino)propoxy]-3-phenylpropiophenonePercent Composition: C 73.87%, H 7.97%...
Literature References: Sodium channel blocker. Prepn: R. Sachse, DE 2001431 (1971 to Helopharm), C.A. 75, 151538f (1971). Pharmacology: H.-J. Hapke, E. Prigge, Arzneim.-Forsch. 26, 1849 (1976). Pharmacokinetics: M. Hollmann et al., ibid. 33, 763 (1983). HPLC determn in plasma and urine: U. Hofmann et al., J. Chromatogr. B 748, 113 (2000). Review of pharmacology and therapeutic efficacy: H. M. Bryson et al., Drugs 45, 85-130 (1993). Review of clinical trials in supraventricular arrhythmias and atrial fibrillation: A. P. Rae, Am. J. Cardiol. 82, 59N-65N (1998); S. C. Reimold et al., ibid. 66N-71N.

Pentisomide CAS Registry Number: 78833-03-1 喷替索胺

CAS Name: a-[2-[Bis(1-methylethyl)amino]ethyl]-a-(2-methylpropyl)-2-pyridineacetamide
Additional Names: 2-[2-(diisopropylamino)ethyl]-4-methyl-2-(2-pyridyl)pentanamide; propisomide; penticainid...
Literature References: Sodium channel blocker; derivative of disopyramide, q.v. Prepn: H. Demarne et al., EP 27412; eidem, US 4356177 (1981, 1982 both to C. M. Industries); C. A. Bernhart et al., J. Med. Chem. 26, 451 (1983). Electrophysiological study: V. Kühlkamp et al., Int. J. Cardiol. 36, 69 (1992). HPLC determn in plasma, urine, and tissues: T. A. Plomp, M. J. H. Buijs, J. Chromatogr. 612, 123 (1993). Clinical evaluation: S. G. Priori et al., Am. J. Cardiol. 60, 1068 (1987); S. G. Mangini et al., Eur. Heart J. 12, 712 (1991). Review: S. Yuan, S. B. Olsson, Cardiovasc. Drug Rev. 11, 74-93 (1993).

Sodium Hypophosphite CAS Registry Number: 7681-53-0 次磷酸钠

CAS Name: Phosphinic acid, sodium salt
Percent Composition: H 2.29%, Na 26.13%, O 36.37%, P 35.21%
Literature References: Solubility data: Palit, J. Am. Chem. Soc. 69, 3120 (1947).